Recent Finacing
Recent Raise
Oncovita, an Institut Pasteur spin-off, develops MeasovirR-modified measles-virus therapeutic and prophylactic cancer vaccines, advancing lead candidate MVdeltaC through preclinical safety, manufacturing scale-up, and planned 2025 Phase 1/2a basket trial.
